Sign inCreate account

Report workspace tools

NCT03029247COMPLETEDanonymous

A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia in Chronic Kidney Disease (CKD)

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

Daprodustat, Epoetin alfa

Source & freshness

Source record

NCT ID

NCT03029247

Original source

ClinicalTrials.gov

Source last updated

Jun 03, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03029247

Title

A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase 2

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

Anemia in Chronic Kidney Disease (CKD)

Target normalized

Anemia in Chronic Kidney Disease (CKD)

Interventions

Daprodustat, Epoetin alfa

Public preview

Source record

The ASCEND-BP study evaluated daprodustat, a novel prolyl hydroxylase inhibitor, against epoetin alfa in managing blood pressure in hemodialysis patients with anemia due to CKD. The study was sponsored by GlaxoSmithKline and involved 105 participants, with a focus on the drug's impact on systolic blood pressure.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03029247

Status

COMPLETED

Phase

Phase 2

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

The ASCEND-BP study evaluated daprodustat, a novel prolyl hydroxylase inhibitor, against epoetin alfa in managing blood pressure in hemodialysis patients with anemia due to CKD. The study was sponsored by GlaxoSmithKline and involved 105 participants, with a focus on the drug's impact on systolic blood pressure.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 03, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03029247

Indication

Anaemia

Modality

small molecule

Target

Anemia in Chronic Kidney Disease (CKD)

Intervention

Daprodustat, Epoetin alfa

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.